APA (7th ed.) Citation

Griesinger, F., Curigliano, G., Thomas, M., Subbiah, V., Baik, C. S., Tan, D. S. W., . . . Mazières, J. (2022). Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: Update from the ARROW trial. Annals of oncology, 33(11), . https://doi.org/10.1016/j.annonc.2022.08.002

Chicago Style (17th ed.) Citation

Griesinger, Frank, et al. "Safety and Efficacy of Pralsetinib in RET Fusion-positive Non-small-cell Lung Cancer Including as First-line Therapy: Update from the ARROW Trial." Annals of Oncology 33, no. 11 (2022). https://doi.org/10.1016/j.annonc.2022.08.002.

MLA (9th ed.) Citation

Griesinger, Frank, et al. "Safety and Efficacy of Pralsetinib in RET Fusion-positive Non-small-cell Lung Cancer Including as First-line Therapy: Update from the ARROW Trial." Annals of Oncology, vol. 33, no. 11, 2022, https://doi.org/10.1016/j.annonc.2022.08.002.